

Lipoprotein Lipase Activity Determined *in vivo* Is Lower in Carriers of Apolipoprotein A-V Gene Variants 19W and -1131C

J. KOVÁŘ^{1,2}, V. ADÁMKOVÁ¹

¹Institute for Clinical and Experimental Medicine, Prague, ²Centre for Cardiovascular Research, Prague, Czech Republic

Received March 14, 2007

Accepted June 6, 2007

On-line July 26, 2007

Summary

The apolipoprotein A-V (apo A-V) plays an important role in regulation of triglyceride (TG) concentration in serum. To better understand how apo A-V affects triglyceridemia and glucoregulation, the lipoprotein lipase (LPL) activity was determined using intravenous fat tolerance test (IVFTT) and oral glucose tolerance test (oGTT) was performed in carriers of apolipoprotein A-V gene (*APOAIV*) variants known to be associated with increased triglyceridemia. Twelve carriers of 19W variant, 16 carriers of -1131C variant, 1 combined heterozygote and 16 control subjects homozygous for wild type variants (19S/-1131T) were selected from a population sample and matched with respect to body mass index and age. The *APOAIV* variants carriers had increased TG, very low density lipoprotein-TG, and apo B concentrations ($p < 0.05$). The LPL activity evaluated as k_2 rate constant for clearance of Intralipid® was 14 % lower in *APOAIV* variants carriers. The depression of nonesterified fatty acids (NEFA) concentration after glucose load was delayed in *APOAIV* variants carriers in spite of the same insulinemia and glycemia. Our results suggest that variants of *APOAIV* combined with increased triglyceridemia are associated with lower LPL activity *in vivo* and with disturbances of regulation of NEFA concentration after glucose load.

Key words

Apolipoprotein A-V • Genetics • Lipoprotein lipase • Nonesterified fatty acids

Corresponding author

J. Kovář, Institute for Clinical and Experimental Medicine, Laboratory for Atherosclerosis Research, Vídeňská 1958/9, 14021 Prague 4, Czech Republic. Fax: +420 241721666. E-mail: jan.kovar@medicon.cz

Introduction

Apolipoprotein A-V (apo A-V), a recently discovered member of apolipoprotein family (Pennacchio *et al.* 2001, van der Vliet 2001, for review see Šeda and Šedová 2003), is a new important player in the regulation of lipoprotein metabolism. It has been suggested that this apolipoprotein is involved in the lipoprotein lipase (LPL) activation (Fruchart-Najib *et al.* 2004, Merkel *et al.* 2005) or in the control of hepatic very low density lipoprotein (VLDL) assembly and/or secretion (Weinberg *et al.* 2003). However, the exact mechanism of apo A-V action has not been clarified yet. Importantly, two variants of human apolipoprotein A-V gene (*APOAIV*), -1131T/C and 19S/W, were found to be associated with increased triglyceridemia in population studies (Pennacchio *et al.* 2002, Hubáček *et al.* 2004). The same variants are more frequent among the patients with extreme hypertriglyceridemia (Hořinek *et al.* 2003, Vrablík *et al.* 2003) and it can be assumed that -1131C and 19W variants are dysfunctional with respect to regulation of triglyceridemia. Therefore, to better understand the role that these variants play in the regulation of lipoprotein lipase activity, the intravenous fat tolerance test (IVFTT) was carried out in both -1131C and 19W variant carriers and in control subjects to determine the LPL activity *in vivo*. Moreover, it has been shown recently that heterozygous LPL deficiency, another genetic defect associated with the development of milder forms of hypertriglyceridemia, can contribute to development of insulin resistance (Holzl *et al.* 2002). To determine whether these *APOAIV* variants can affect the glucoregulation, the oral glucose tolerance test (oGTT) was carried out in the same subjects.

Table 1. The age, body mass index (BMI) and waist-hip ratio (WHR) in control subjects and *APOAV* variants carriers included into the study.

	Subjects					p
	Controls	Carriers of <i>APOAV</i> variants				
		All	19W	-1131C	19W/-1131C	
<i>n</i>	16	29	12	16	1	
age [years]	52.8±10.2	52.5±9.1	53.7±9.4	51.0±9.0	61.0	n.s.
BMI [kg/m ²]	28.7±2.6	29.0±3.5	29.8±3.2	28.1±3.5	33.6	n.s.
waist [cm]	98±8	96±8	98±9	95±8	108	n.s.
WHR	0.93±0.05	0.92±0.05	0.92±0.05	0.92±0.04	0.95	n.s.

Data are means ± S.D. The differences between control subjects and all *APOAV* variants carriers were evaluated using t test, the differences between three subgroups (controls, 19W, and -1131C carriers) using ANOVA. p - probability of differences between groups detected using ANOVA or Kruskal-Wallis statistic.

Methods

Subjects and design of the study

Subjects, carriers of *APOAV* variants, were selected from a 1 % population sample of two districts in Czech Republic originally examined in Czech MONICA follow-up study (Cífková and Škodová 2004) in 1997 and 1998. They were invited for another examination 7 or 8 years later. The control subjects (homozygous for 19S and -1131T variants) were selected from the same population sample. They were matched to *APOAV* variants carriers with respect to age and body mass index (BMI) determined at the time of their examination during the population study and they did not differ in these parameters at the entry into the study (Table 1). The 19S/W and -1131T/C polymorphisms of *APOAV* gene and apolipoprotein E gene (*APOE*) polymorphism were determined in the above mentioned population study (Hubáček *et al.* 2004). Twelve carriers of 19W allele (all of them heterozygous), 16 carriers of -1131C allele, one subject heterozygous for 19W/-1131C and 16 control subjects (homozygous for both 19S and -1131T variants) were recruited. Five subjects were homozygous for -1131C allele. They did not differ from heterozygous carriers in age, anthropometric parameters, lipids and lipoproteins and, therefore, homo- and heterozygous carriers of -1131C allele were pooled for statistical analysis.

All subjects included into the study were examined twice. On the first occasion, they underwent clinical examination and the fasting blood for

determination of lipids in serum was obtained. Oral glucose tolerance test was then carried out. At the second visit, fasting blood was obtained for isolation of lipoproteins by ultracentrifugation and intravenous fat tolerance test was carried out to determine LPL activity *in vivo*. The study protocol was approved by the Ethical Committee of the Institute for Clinical and Experimental Medicine and all the participants gave their informed consent.

Methods

The standard oral glucose tolerance test (oGTT) (75 g of glucose) was carried out and blood for determination of glucose, insulin and nonesterified fatty acids (NEFA) in serum was collected before and 30, 60 and 120 min after glucose load.

Intravenous fat tolerance test (IVFTT) was carried out as previously described (Rössner 1974) with slight modifications (Jindřichová *et al.* 2007). Intralipid® (0.1 g of fat/kg of body weight) was injected to subjects and blood for nephelometric determination of k_2 rate constant was collected before application and then for 40 min after application in 5min intervals. The turbidity of diluted serum was measured on MARK IV nephelometer (Scientific Furnishings LTd, England). The k_2 rate constant is considered to be the measure of LPL activity *in vivo*.

Very low density lipoproteins (VLDL) were isolated by ultracentrifugation (Havel *et al.* 1955).

Cholesterol and triglycerides in serum and VLDL were determined using enzymatic kits from

Table 2. Concentration of lipids, lipoproteins and apo B in control subjects and *APOAV* variants carriers included into the study.

	Subjects					p
	Controls	Carriers of <i>APOAV</i> variants				
		All	19W	-1131C	19W/-1131C	
<i>n</i>	16	29	12	16	1	
TG (mmol/l)	1.57±0.68 [1.45]	3.29±4.09* [1.93]	3.84±3.85 [2.88]	2.98±4.46 [1.76]	1.89	< 0.10
cholesterol (mmol/l)	5.62±1.01	6.10±1.32	6.02±1.40	6.21±1.32	5.29	n.s.
HDL-C (mmol/l)	1.31±0.24	1.28±0.39	1.28±0.48	1.31±0.31	0.81	n.s.
LDL-C (mmol/l)	3.55±0.86	3.60±0.91	3.33±0.89	3.80±0.94	3.62	n.s.
apo B (g/l)	1.09±0.25	1.33±0.45*	1.45±0.64	1.24±0.22	1.23	n.s.
VLDL-TG (mmol/l)	1.01±0.50 [1.02]	2.68±5.24* [1.52]	1.73±0.96 [1.76]	3.20±6.53 [1.52]	1.89	< 0.05
VLDL-C (mmol/l)	0.43±0.20 [0.41]	0.79±1.11 [0.64]	0.49±0.33 [0.35]	0.95±1.36 [0.64]	0.67	< 0.10
VLDL-C/VLDL-TG	0.45±0.09 ^a	0.36±0.10*	0.30±0.12 ^b	0.39±0.08 ^{a,b}	0.35	< 0.01

Data are means ± S.D. [medians]. The medians are shown for variables with non Gaussian distribution. The differences between control subjects and all *APOAV* variants carriers were evaluated using t test except of TG, VLDL-TG, and VLDL-C concentrations when Mann-Whitney test was used. The differences between three subgroups (controls, 19W, and -1131C carriers) were evaluated using ANOVA or Kruskal-Wallis statistic (TG, VLDL-TG, VLDL-C). The t test with Bonferroni correction or the Dunn's test, respectively, were used for multiple comparisons if appropriate. * - $p < 0.05$ - controls vs all *APOAV* variants carriers. p - probability of differences between groups detected using ANOVA or Kruskal-Wallis statistic, ^{a,b} - the same letters belongs to groups (controls, 19W carriers, -1131C carriers) that do not differ.

Roche Diagnostics, Switzerland. High density lipoprotein-cholesterol (HDL-C) was measured after precipitation of lipoproteins containing apolipoprotein B (apo B) using enzymatic kits from the same provider and low density lipoprotein-cholesterol (LDL-C) was then calculated using Friedewald formula. Glucose concentration was determined by enzymatic kits from LACHEMA, Czech Republic, nonesterified fatty acids (NEFA) by enzymatic kits from Wako Chemicals GmbH, Germany, and apo B was determined by kits from Orion Diagnostica, Finland.

Statistics

Depending on the data distribution, the differences between control subjects and all *APOAV* variants carriers were evaluated using t-test or Mann-Whitney test. To detect differences between controls, 19W and -1131C variant carriers, the ANOVA or Kruskal-Wallis statistic were used. When needed, multiple comparisons were carried out using t-test with Bonferroni correction or Dunn's test, respectively (Glantz 1992).

Results

The *APOAV* variants carriers had increased concentration of triglycerides, VLDL-TG, apolipoprotein B and had lower ratio VLDL-C/VLDL-TG than control subjects (Table 2). The statistical significance of differences in TG concentration disappeared when *APOAV* variants carriers were further subdivided likely due to a smaller sample size. Also, the variability of triglyceridemia was more pronounced in *APOAV* variants carriers – 12 out of 29 *APOAV* variant carriers had TG concentration higher than 2 mmol/l (compared to 2 out of 16 controls), pronounced hypertriglyceridemia (TG > 4 mmol/l) was detected in 4 carriers and none of the controls. Importantly, there were no differences between 5 homozygous and 11 heterozygous -1131C allele carriers in any of analyzed parameters and therefore they were pooled for the analysis.

Remarkably, there were 4 diabetics and 13 subjects with impaired glucose tolerance among the subjects included into the study, 1 and 5 among 19W variant carriers, 2 and 4 among -1131C variant carriers

Table 3. Lipoprotein lipase activity determined as k_2 rate constant in intravenous fat tolerance test, changes of glucose, insulin and NEFA concentrations during oral glucose tolerance test and HOMA index in control subjects and carriers of *APOAIV* variants.

	Subjects					p	
	Controls	Carriers of <i>APOAIV</i> variants			5.02		
		All	19W	-1131C			19W/-1131C
Intravenous fat tolerance test (IVFTT)							
k_2 [%/min]	4.69±1.15	3.93±1.73*	4.40±2.46	3.60±1.19	5.02	< 0.10	
Oral glucose tolerance test (oGTT)							
	Time [min]						
<i>glucose</i> [mmol/l]	0	5.9±1.1	6.0±2.7	6.7±3.8	5.5±1.4	5.7	n.s.
	30	9.6±2.0	10.4±3.1	11.5±3.9	9.7±2.3	9.1	n.s.
	60	9.0±2.0	10.9±4.5	12.6±4.9	9.7±4.0	10.7	n.s.
	120	6.1±2.0	7.3±5.1	8.7±7.3	6.4±2.7	5.5	n.s.
<i>insulin</i> [mIU/l]	0	10±8	9±5	11±6	7±4	18	n.s.
	30	62±51	52±33	58±41	45±26	77	n.s.
	60	65±37	69±53	89±67	49±29	138	< 0.10
	120	33±34	32±27	45±36	22±13	40	n.s.
<i>NEFA</i> [mmol/l]	0	0.45±0.27	0.53±0.28	0.52±0.27	0.54±0.30	0.47	n.s.
	30	0.20±0.09 ^a	0.42±0.34**	0.44±0.42 ^b	0.41±0.29 ^b	0.47	< 0.01
	60	0.10±0.07 ^a	0.22±0.23**	0.24±0.23 ^b	0.20±0.24 ^{a,b}	0.11	< 0.05
	120	0.06±0.03	0.13±0.19	0.14±0.20	0.13±0.20	0.06	n.s.
<i>HOMA index</i>		2.72±2.48	2.67±2.51	3.68±3.24	1.75±1.39	4.48	n.s.

Data are means ± S.D. The differences between control subjects and all *APOAIV* variants carriers were evaluated using Mann-Whitney test. Kruskal-Wallis statistic was used to detect differences between controls, 19W and -1131C carriers and the Dunn's test was used for multiple comparisons when appropriate. *, ** - $p < 0.05$, $p < 0.01$, respectively - controls vs all *APOAIV* variants carriers (Mann-Whitney test). p - probability of differences between groups detected using Kruskal-Wallis statistic, ^{a,b} - the same letters belongs to groups (controls, 19W carriers, -1131C carriers) that do not differ.

and 1 and 4 among controls, respectively. However, none of the subjects was treated for diabetes and/or glucose intolerance at the entry into the study.

The k_2 rate constant, the measure of LPL activity determined *in vivo* in intravenous fat tolerance test, was decreased in carriers of *APOAIV* variants (Table 3). The difference did not remain significant when the carriers were subdivided into subgroups (19W and -1131C) ($p < 0.10$) likely because of the small size of the subgroups and due to the fact that highest k_2 value in the study ($k_2 = 10.2$ %/min) was found in one of the 19W allele carriers (Table 3).

There was no difference either in the course of glycemia and insulinemia or in the HOMA index between *APOAIV* variants carriers and controls (Table 3). However, the depression of serum NEFA concentration after oral glucose load was markedly delayed in both 19W and -1131C allele carriers (Table 3).

Discussion

To summarize, we have found that LPL activity determined *in vivo* using intravenous fat tolerance test is lower in subjects carrying 19W or -1131C allele of *APOAIV*

gene than in carriers of wild type *APOAV* variants. Moreover, although we did not detect any differences in insulin resistance between control subjects and carriers of 19W and -1131C *APOAV* variants, the suppression of serum nonesterified fatty acid concentration after oral glucose administration was markedly delayed in *APOAV* variants carriers.

Up to now, the evidence that apo A-V can activate LPL has been growing up. However, the role of apo A-V in the process is quite different than that of apo C-II. Although the first papers on the topic were not very convincing because of supraphysiological concentrations of apo A-V (Fruchart-Najib *et al.* 2004, Schaap *et al.* 2004), there are recent data suggesting that apo A-V can facilitate interaction between VLDL, LPL and heparan sulfate at the endothelium (Merkel *et al.* 2005). The different role of apo A-V in LPL activation is underlined by the fact that it cannot prevent development of hyperchylomicronemia in apo C-II deficient subjects. However, up to now there has been no evidence that LPL activity is affected by apo A-V in humans. Our data obtained using IVFTT show that LPL activity is indeed lower in those carrying *APOAV* variants known to be associated with hypertriglyceridemia. It should be stressed that results of IVFTT reflect the LPL activity *in vivo* contrary to the measurement of LPL *in vitro*, which corresponds to the amount of active form of enzyme released into circulation by heparin. *In vitro* measurement cannot reflect the factors affecting LPL activity *in situ* such as blood flow rate and the complex interactions between all the components of the lipolytic system including LPL, VLDL, heparan sulphate, availability of apo C-II, the rate of transfer of fatty acids released from the site of hydrolysis and others.

It has been suggested that 19W variant is not secreted efficiently from the liver and, therefore, may have a lower concentration in circulation (Talmud *et al.* 2005). Although the same authors were unable to identify any exact role for -1131C variant, they pointed out that this variant is a part of more complex haplotype *APOAV**2. This haplotype is in linkage disequilibrium with apo C-III variant defective with respect to downregulation by insulin (Waterworth *et al.* 2003) – the inhibition of LPL may result from the increased apo C-III concentration in circulation. In spite of possible differences in the effect of -1131C and 19W *APOAV* variants on metabolism of triglyceride-rich lipoproteins, we were unable to detect any differences between these *APOAV* variants in their effect on lipoprotein metabolism in our study.

Although there are no differences in the insulinemia and glycemia after oral glucose load between carriers of *APOAV* variants and control subjects, there are profound differences in the nonesterified fatty acids concentration. Concerning the mechanism of delayed suppression of NEFA concentration after oral glucose load, we do not have any data to provide an explanation. It is generally accepted that NEFA in circulation originate from lipolysis in adipose tissue, which is tightly inhibited by insulin – that was actually observed in control subjects in the study. The findings of delayed suppression of NEFA concentration after oral glucose load in *APOAV* variants carriers might suggest that the regulation of lipolysis in adipose tissue by insulin is defective in these subjects. Nevertheless, the mechanism of that is puzzling because we have not seen any differences in insulinemia and glycemia. If insulin action on lipolysis in adipose tissue is the same in all the subjects, it could be then speculated that higher concentration of NEFA in circulation after glucose load may rather reflect the increased leakage of fatty acids released by LPL into circulation. If this is the case, apo A-V might be involved in some way in directing fatty acids from the site of lipolysis at the endothelial surface to the tissue. It could also be speculated that, if the concentration of NEFA is higher in subjects with *APOAV* variants throughout the day, the VLDL production should be also increased and contribute to hypertriglyceridemia.

It should also be noted that the lower VLDL-C/VLDL-TG ratio along with pronounced triglyceridemia suggest that *APOAV* variants carriers have on average larger VLDL particles than control subjects. Moreover, the fact that *APOAV* variants carriers have the same LDL-C together with increased apo B concentration implies that they have higher proportion of small dense LDL particles in circulation than the carriers of wild type alleles of *APOAV*. Such lipoprotein profile could contribute to a higher risk of cardiovascular disease in *APOAV* variants carriers, but our findings need to be confirmed in other studies.

In conclusion, for the first time it has been documented that subjects carrying 19W and -1131C variant of *APOAV* gene have lower LPL activity *in vivo* than those having wild type *APOAV*. The subjects carrying 19W and -1131C alleles were also found to have defective regulation of nonesterified fatty acid concentration after glucose load.

Conflict of Interest

There is no conflict of interest.

Acknowledgements

The authors thank to Hana Kocandová, Irena Houšťková, and Dana Körberová for their excellent technical

assistance. The study was supported by grant # NR/7923-3 from IGA MH CR.

References

- CÍFKOVÁ R, ŠKODOVÁ Z: Longitudinal trends in major cardiovascular disease risk factors in the Czech population. (in Czech) *Čas Lék Čes* **143**: 219-226, 2004.
- FRUCHART-NAJIB J, BAUGE E, NICULESCU LS, PHAM T, THOMAS B, ROMMENS C, MAJD Z, BREWER B, PENNACCHIO LA, FRUCHART JC: Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. *Biochem Biophys Res Commun* **319**: 397-404, 2004.
- GLANTZ SA: *Primer of Biostatistics*. McGraw-Hill, New York, 1992.
- HAVEL RJ, EDER HA, BRAGDON JH: The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. *J Clin Invest* **34**: 1345-1353, 1955.
- HOLZL B, IGLSEDER B, SANDHOFER A, MALAIMARE L, LANG J, PAULWEBER B, SANDHOFER F: Insulin sensitivity is impaired in heterozygous carriers of lipoprotein lipase deficiency. *Diabetologia* **45**: 378-384, 2002.
- HOŘÍNEK A, VRABLÍK M, ČEŠKA R, ADÁMKOVÁ V, POLEDNE R, HUBÁČEK JA: T-1131-->C polymorphism within the apolipoprotein AV gene in hypertriglyceridemic individuals. *Atherosclerosis* **167**: 369-370, 2003.
- HUBÁČEK JA, ŠKODOVÁ Z, ADÁMKOVÁ V, LÁNSKÁ V, POLEDNE R: The influence of APOAV polymorphisms (T-1131>C and S19>W) on plasma triglyceride levels and risk of myocardial infarction. *Clin Genet* **65**: 126-130, 2004.
- JINDŘICHOVÁ E, KRATOCHVÍLOVÁ S, KOVÁŘ J: Glucose administration downregulates lipoprotein lipase activity in vivo: a study using repeated intravenous fat tolerance test. *Physiol Res* **56**: 175-181, 2007.
- PENNACCHIO LA, OLIVIER M, HUBACEK JA, COHEN JC, COX DR, FRUCHART JC, KRAUSS RM, RUBIN EM: An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. *Science* **294**: 169-173, 2001.
- PENNACCHIO LA, OLIVIER M, HUBÁČEK JA, KRAUSS RM, RUBIN EM, COHEN JC: Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. *Hum Mol Genet* **11**: 3031-3038, 2002.
- MERKEL M, LOEFFLER B, KLUGER M, FABIG N, GEPPERT G, PENNACCHIO LA, LAATSCH A, HEEREN J: Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. *J Biol Chem* **280**: 21553-21560, 2005.
- RÖSSNER S: Studies on an intravenous fat tolerance test. Methodological, experimental and clinical experiences with Intralipid. *Acta Med Scand Suppl* **564**: 1-24, 1974.
- ŠEDA O, ŠEDOVÁ L: New apolipoprotein A-V: comparative genomics meets metabolism. *Physiol Res* **52**: 141-146, 2003.
- SCHAAP FG, RENSEN PC, VOSHOL PJ, VRINS C, VAN DER VLIET HN, CHAMULEAU RA, HAVEKES LM, GROEN AK, VAN DIJK KW: ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. *J Biol Chem* **279**: 27941-27947, 2004.
- TALMUD PJ, PALMEN J, PUTT W, LINS L, HUMPHRIES SE: Determination of the functionality of common APOA5 polymorphisms. *J Biol Chem* **280**: 28215-28220, 2005.
- VAN DER VLIET HN, SAMMELS MG, LEEGWATER AC, LEVELS JH, REITSMA PH, BOERS W, CHAMULEAU RA: Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. *J Biol Chem* **276**: 44512-44520, 2001.
- VRABLÍK M, HOŘÍNEK A, ČEŠKA R, ADÁMKOVÁ V, POLEDNE R, HUBÁČEK JA: Ser19-->Trp polymorphism within the apolipoprotein AV gene in hypertriglyceridaemic people. *J Med Genet* **40**: e105, 2003.

WATERWORTH DM, TALMUD PJ, LUAN J, FLAVELL DM, BYRNE CD, HUMPHRIES SE, WAREHAM NJ: Variants in the APOC3 promoter insulin responsive element modulate insulin secretion and lipids in middle-aged men. *Biochim Biophys Acta* **1637**: 200-206, 2003.

WEINBERG RB, COOK VR, BECKSTEAD JA, MARTIN DD, GALLAGHER JW, SHELNESS GS, RYAN RO: Structure and interfacial properties of human apolipoprotein A-V. *J Biol Chem* **278**: 34438-34444, 2003.
